Active substance
Valbenazine
- US FDA 4
- US price lines 3
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| INGREZZA | EQ 40MG BASE; EQ 80MG BASE; EQ 60MG BASE | capsule · oral | NEUROCRINE | Prescription | 11 Apr 2017 |
| VALBENAZINE TOSYLATE | EQ 40MG BASE; EQ 80MG BASE; EQ 60MG BASE | capsule · oral | LUPIN | Prescription | 5 Apr 2024 |
| INGREZZA SPRINKLE | EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE | capsule · oral | NEUROCRINE | Prescription | 30 Apr 2024 |
| VALBENAZINE TOSYLATE | EQ 40MG BASE; EQ 60MG BASE; EQ 80MG BASE | capsule · oral | ZYDUS LIFESCIENCES | Discontinued | 7 Aug 2024 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | INGREZZA 40 MG CAPSULE | $258.94167 | per EA | 23 Sep 2026 |
| US NADAC | INGREZZA 60 MG CAPSULE | $283.324 | per EA | 23 Sep 2026 |
| US NADAC | INGREZZA 80 MG CAPSULE | $283.324 | per EA | 23 Sep 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 4 Feb 2025 INGREZZA — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.